---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-023218"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T20:44:23.208724+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Milestone reports Q4 2024 net loss $12.4M; FDA PDUFA date for CARDAMYST is March 27, 2025

## Summary
- FDA PDUFA goal date for CARDAMYST (etripamil) in PSVT is March 27, 2025; launch targeted for mid-2025 if approved.
- Cash, cash equivalents, and short-term investments: $69.7M as of Dec 31, 2024, vs $66.0M year-end 2023.
- Q4 2024 net loss $12.4M ($0.19/share), improved from $13.6M ($0.32/share) in Q4 2023.
- Full year 2024 net loss $41.5M ($0.67/share), vs $59.7M ($1.39/share) in 2023; revenue zero.
- Phase 3 trial for etripamil in AFib-RVR on track to initiate in 2025 with patient self-administration regimen.

## SEC filing metadata
- accession: 0001104659-25-023218
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465925023218/0001104659-25-023218-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465925023218/tm259067d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-023218
- JSON: https://secwatch.observer/filing/0001104659-25-023218.json
- Plain text: https://secwatch.observer/filing/0001104659-25-023218.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.